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Conclusions: The SourceCheck 4Pi ionization chamber shows 
an additional dependence with the air density which is 
clearly linear. The air density dependence of the three 
analyzed chambers can be represented by the same function, 
showing that there is not a significative variability between 
them regarding this dependence. 
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Purpose/Objective: A multicentre audit to evaluate HDR and 
PDR brachytherapy using alanine and ion chamber absolute 
dosimetry. This is the first National UK audit of its type, 
performed for both INTERLACE and non-INTERLACE study 
centres treating gynaecological tumours using brachytherapy. 
Materials and Methods: 45 UK brachytherapy centres were 
visited from October 2013 to August 2014. A variety of source 
types including: 7 Flexisource, 23 mHDR-v2, 11 GammaMed 
HDR Plus, 2 GammaMed PDR Plus, one VS2000 and one 
Co0.A86 were audited. A virtual line source was generated 
within each centre's planning system using 11 dwell positions, 
5 mm apart, and dwell times calculated to deliver 10 Gy 20 
mm away from the midpoint of the central dwell. This is 
equivalent to Point A of the Manchester system. The line 
source was delivered in a Solid WaterTM phantom [Aird et al, 
EP-1924. Radiat Oncol April 2014;111(S1):752] and absorbed 
dose measured with both an ion chamber (PTW TW30012) and 
alanine. Charge was measured in 3 positions (120° apart, 20 
mm from source) and averaged to reduce source geometric 
variations. A further measurement point was created at 50 
mm from the source to determine absorbed dose at the 
equivalent of Point B of the Manchester system. 
Results: Ion chamber measurements for all centres showed a 
mean difference (±sd) of +0.9% (±1.2) and +1.3% (±1.4) when 
compared to the centres' calculated dose at 20 mm and 50 
mm, respectively. The mean alanine measurement at Point A 
was +2.0% (±1.5). There was a noticeable difference between 
source types, see Table 1. Furthermore, there were large 
discrepancies in dose measured in each of the three holes 
due to positional variation of the source within the catheter 
and anisotropy of the source, ranging from +0.4 to 4.9% 
maximum difference between two holes. 
 
Conclusions: A comprehensive audit of absolute dose to 
water from a line brachytherapy source was performed 
showing all centres could deliver the prescribed dose to 
within 5%. There was a significant positional variation of the 
source detected in the measurements and differences were 
also seen between the source types.  
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Purpose/Objective: Due to the high risk of complications 
resulting from an incorrect treatment of High Dose Rate 
(HDR) Brachytherapy, it is essential that methods and 
instrumentation for quality assurance (QA) are available to 
medical physicists. Direct and accurate verification the 
treatment plan delivery and the functionality of the remote 
afterloader are of paramount importance in ensuring 
appropriate treatment. Currently, there are no 
comprehensive QA solutions available for HDR brachytherapy. 
Materials and Methods: A novel QA device, named 'magic 
phantom' (MPh), has been developed which will allow for the 
pre-treatment delivery verification of plans in HDR 
brachytherapy. It assesses source dwell positions and times, 
and potential differences in planned and calculated delivered 
dose. The MPh system comprises of a two-dimensional array 
of 121 silicon diode detectors with low noise and fast readout 
electronics, a measurement and analysis software toolkit, 
and a portable Perspex phantom. The detector array is 
inserted within the phantom, between two rows of HDR 
brachytherapy catheters, allowing for the verification of 
treatment plans with up to 20 catheters. 
A 20 catheter plan was generated to simulate a nonspecific 
patient treatment scenario. This was delivered to the MPh 
and using a developed four-dimensional source tracking 
algorithm, the treatment dwell position and times were 
determined in post-processing. A new metric, the 'position-
time gamma index', was developed to quantify the quality of 
the measured delivery when compared to the treatment 
plan. The original plan dwell positions and timing patterns 
were then modified to simulate multiple afterloader delivery 
errors. These changes were not disclosed to the investigators, 
and were to be determined by the MPh measurement. 
Results: The device was shown to determine dwell times as 
short as 0.06 s and dwell positions separated by 1 mm. For 
the original plan, the MPh measured all dwell positions and 
times, with the majority found to be within 0.93 mm and 
0.25 s from the planned, respectively. By assessing the 
altered plan and comparing it to the unmodified, the use of 
the position-time gamma index showed that all amendments 
made could be easily detected. Seen in Fig. 1, all 11 
S140                                                                                                                                         3rd ESTRO Forum 2015 
 
simulated errors had gamma values greater than 1, and fail 
the criteria. In addition to dwell positions and times analysis, 
the system was capable of determining the transit time 
between dwell positions and its effect on the estimated dose 
delivered when compared against the treatment plan. 
 
Figure 1 - The position-time gamma analysis of the modified 
plan. 
Conclusions: Our application of the developed quality 
assurance system 'magic phantom', to HDR brachytherapy has 
demonstrated ability to perform the verification of all HDR 
treatment plans. This device has shown potential to be the 
comprehensive QA solution for the entire treatment delivery, 
with further development of this system focused on real time 
in vivo source tracking.  
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Purpose/Objective: One of the important proceedings of 
brachytherapy during the last years was the clinical 
implementation of modern planning algorithms. To provide 
guidelines to the medical physicist the AAPM TG-186 
published a report that describes procedures for 
commissioning new treatment planning algorithms (TPSs) in 
brachytherapy. To evaluate the guidance of this report from 
the end-users perspective we describe in this work the 
commissioning process of a commercial model-based dose 
calculation algorithm (MBDCA) for an HDR afterloading device 
in our clinic according to TG-186. We furthermore study 
complemental dose measurements. 
Materials and Methods:The TPS BrachyVision v11.0.47 
utilizing the dose calculation algorithm Acuros v1.5.0 for an 
Ir-192 HDR GammaMedplus afterloader (Varian Medical 
System, Palo Alto, CA) was used for this study. In the first 
step the commissioning process, as recommended by the TG-
186 report, was followed for level 1. Dose comparisons 
between TG-43 formalism and Acuros were carried out in 
water medium for a single source scenario of 40700 U. 
Moreover hand calculations were performed for several 
points of interest using along away table for the relevant TG-
43 consensus data. 
Measurements in a water tank (40x40x40 cm3) using a 
Semiflex chamber, type 31010, (PTW Freiburg, Germany) 
were conducted. Dose measurements are in particular of 
interest to validate the impact of heterogeneities in the 
Acuros module. They were carried out at various points of 
interest, laterally and distally positioned from the source. 
Therefor the source was either positioned in an implant 
needle made of steel or in a shielded 90° vaginal cylinder of 
3.5 cm diameter. This shielded cylinder is also virtually 
available for dose calculation as template in the applicator 
library of the BrachyVision/Acuros system. 
Results: Results of computations and measurements in water 
are summarized in Table 1. Hand and TG-43 based 
calculations are close to results of the Acuros computations 
(better than 2% for all points). As expected, dose 
measurements close to the source show deviations (about 
30% at 1,14 cm), but reached reasonable accuracy at longer 
distances (e.g. 5% at 7,11 cm). 
Dose values behind the shielding of the vaginal applicator are 
shown in Figure 1. Good agreement was reached between 
measurements and the results of the MBDCA. TG-43 
formalism takes heterogeneities not in to account, so the 
computed doses are not accurate behind the shielding. 
 
 
Conclusions: Commissioning of a MBDCA is well feasible when 
following the TG-186 report, level 1. In addition dose 
measurements in water can complete the procedure to check 
the impact of heterogeneities in the medium. 
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Purpose/Objective: Dose surface maps (DSM) provide spatial 
features of the rectal wall dose distribution which has been 
shown to correlate with tissue toxicity in different ways 
(Buettner et al 2009). This study aims to develop the 
methodology and assess feasibility of using DSM to 
accumulate rectal wall dose from both external beam 
radiotherapy (EBRT) and brachytherapy (BT) in cervical 
cancer patients. This was previously not possible using 
conventional dose volume histogram due to lack of spatial 
information and challenges with anatomical difference 
between the two therapeutic modalities. 
